ResMed (RMD) director exercises 11,442 options and updates holdings

ResMed Inc. director activity: A company director reported option exercises and related share dispositions in ResMed Inc. common stock.

Rhea-AI Filing Summary

ResMed Inc. director activity: A company director reported option exercises and related share dispositions in ResMed Inc. common stock. On 11/14/2025, the director exercised 11,442 stock options at an exercise price of $101.64 per share, adding 11,442 shares to their direct holdings. On the same date, 7,314 shares were disposed of at $244.46 per share to cover tax withholding and the cost to exercise options originally granted on 11/14/2018. After these transactions, the director directly owned 70,238 shares of ResMed common stock, and the reported option grant covering 11,442 shares was fully exercised, leaving 0 derivative securities from that grant.

Insider Trade Summary

11,442 shares exercised/converted

Exercise 3 txns

Insider FARRELL PETER C

Role Director

Type	Security	Shares	Price	Value
Exercise	ResMed Common Stock Options	11,442	$0.00	$0.00
Exercise	ResMed Common Stock	11,442	$101.64	$1.16M
Exercise Price or Tax Liability	ResMed Common Stock	7,314	$244.46	$1.79M

Holdings After Transaction: ResMed Common Stock Options — 0 contracts (Direct); ResMed Common Stock — 70,238 shares (Direct)

Footnotes (3)

1. F1. Transaction represents Options automatically exercised pursuant to the award terms. Options are vested in full.
2. F2. Disposition to issuer for tax withholding and cost to exercise the options granted on 11/14/2018.
3. F3. Transaction represents Options automatically exercised pursuant to the award terms. Options are vested in full.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ResMed (RMD) report in this Form 4?

A ResMed Inc. director reported exercising 11,442 stock options for ResMed common stock on 11/14/2025 and related share dispositions for tax and exercise costs.

How many ResMed (RMD) shares does the reporting person own after the transaction?

Following the reported transactions, the director beneficially owned 70,238 shares of ResMed common stock in direct ownership.

What was the exercise price of the ResMed (RMD) stock options?

The ResMed common stock options were exercised at an exercise price of $101.64 per share, as shown in the derivative securities table.

How many ResMed (RMD) shares were disposed of to cover taxes and exercise costs?

The filing states that 7,314 shares of ResMed common stock were disposed of at $244.46 per share to cover tax withholding and the cost to exercise options granted on 11/14/2018.

What happened to the director’s ResMed (RMD) stock options after this Form 4 transaction?

The option award for 11,442 shares of ResMed common stock was automatically exercised pursuant to the award terms, and after the transaction 0 derivative securities from that grant remained beneficially owned.

What is the role of the reporting person at ResMed (RMD)?

The reporting person is identified as a Director of ResMed Inc. and signs the form as Peter C. Farrell, Chairman emeritus.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/18/2025 - 04:59 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FARRELL PETER C

(Last) (First) (Middle)

9001 SPECTRUM CENTER BLVD.

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	11/14/2025		M(1)		11,442	A	$101.64	77,552	D
ResMed Common Stock	11/14/2025		F(2)		7,314	D	$244.46	70,238	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
ResMed Common Stock Options	$101.64	11/14/2025		M(3)			11,442	11/11/2019	11/14/2025	ResMed Common Stock	11,442	$0	0	D

Explanation of Responses:

1. Transaction represents Options automatically exercised pursuant to the award terms. Options are vested in full.

2. Disposition to issuer for tax withholding and cost to exercise the options granted on 11/14/2018.

3. Transaction represents Options automatically exercised pursuant to the award terms. Options are vested in full.

	Peter C. Farrell, Chairman emeritus	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.